Supplementary Figure S17 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Supplementary Figure S17. CD30-positive B-cell acute lymphoblastic leukemia (B-ALL) burden of two in-vivo models that were being used to test SB9-mediated protection of ‘donor’ cells against allorejection (allorejection model) and AICD (AICD model), respectively. Bioluminescence signals from HLADKO NALM6-CD30.eGFP-ffLuc that were prepared from either FACS (allorejection model) or clonal selection (AICD model) were measured at baseline (day 0). Each point represents an individual mouse. The lines with error bars indicate mean + SD.